



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/517,078	06/02/2005	Donald Keith Martin	FBRIC48.001APC	8640

20995 7590 02/08/2007
KNOBBE MARTENS OLSON & BEAR LLP
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

EXAMINER

MARTIN, PAUL C

ART UNIT	PAPER NUMBER
----------	--------------

1657

SHORTENED STATUTORY PERIOD OF RESPONSE	NOTIFICATION DATE	DELIVERY MODE
3 MONTHS	02/08/2007	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Notice of this Office communication was sent electronically on the above-indicated "Notification Date" and has a shortened statutory period for reply of 3 MONTHS from 02/08/2007.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

jcarter@kmob.com
eOAPilot@kmob.com



UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

10/517078

EXAMINER

ART UNIT	PAPER
----------	-------

20070201

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed on 01/10/07 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): The restriction requirement set forth in the previous action filed 10/05/06 required an election of one species of NSAIDS from among those listed in Claim 126. In the reply dated 01/10/07 the Applicant indicates an election of NSAIDS (Response to Restriction Requirement, Pg. 7, 01/10/07). The election of NSAIDS is non-reponsive since the restriction clearly indicated that an election of species of NSAIDS was required. Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Paul C. Martin whose telephone number is 571-272-3348. The examiner can normally be reached on M-F 8am-4:30pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Paul Martin Examiner
Art Unit 1657
02/01/07

Jon Weber
Supervisory Patent Examiner

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Martin et al.
Appl. No. : 10/517,078
Filed : June 2, 2005
For : NOVEL SCREENS TO IDENTIFY
AGENTS THAT MODULATE
RETINAL BLOOD VESSEL
FUNCTION AND PERICYTE
FUNCTION AND DIAGNOSTIC
AND THERAPEUTIC
APPLICATION THEREFOR
Examiner : Martin, Paul C.
Group Art Unit : 1657

RESPONSE TO OFFICE COMMUNICATION**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Communication mailed February 8, 2007, please amend the above-captioned application as requested in the Response to Restriction Requirement and Amendment filed on January 10, 2007.

Regarding election of a species, the Applicants elect Aspirin. Claims 122-127 read on the elected species. Applicants understand that, upon allowance of a generic claim, the Applicants will be entitled to consideration of claims to additional species that are written in dependent form or otherwise include all limitations of an allowed generic claim as provided by 37 CFR 1.141.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 6, 2007By: Raymond D. Smith

Raymond D. Smith

Registration No. 55,634

Agent of Record

Customer No. 20,995

(805) 547-5580